Standard BioTools Reports Second Quarter 2025 Financial Results
Standard BioTools (NASDAQ:LAB) reported Q2 2025 financial results, highlighting a strategic transformation with the sale of SomaLogic to Illumina for up to $425 million in cash plus future royalties. Q2 revenue from continuing operations was $21.8 million, down 3% year-over-year. The company reported $240 million in cash and expects at least $550 million post-Illumina transaction closure.
Key metrics include consumables revenue of $10.5 million (up 18% YoY), instruments revenue of $5.2 million (down 26% YoY), and services revenue of $6.1 million (down 8% YoY). The company improved its net loss to $17.7 million from $25.4 million in Q2 2024. For FY2025, Standard BioTools expects combined revenue of $165-175 million, with continuing operations revenue of $78-83 million.
Standard BioTools (NASDAQ:LAB) ha pubblicato i risultati finanziari del secondo trimestre 2025, segnando una trasformazione strategica con la cessione di SomaLogic a Illumina per fino a $425 million in contanti più royalties future. I ricavi del Q2 dalle attività continuative sono stati di $21.8 million, in calo del 3% rispetto all'anno precedente. La società dichiara di avere $240 million in liquidità e prevede almeno $550 million al completamento della transazione con Illumina.
I principali indicatori includono ricavi da consumabili per $10.5 million (in aumento del 18% su base annua), ricavi da strumenti per $5.2 million (in calo del 26% su base annua) e ricavi da servizi per $6.1 million (in calo dell'8% su base annua). La perdita netta è migliorata a $17.7 million rispetto a $25.4 million nel Q2 2024. Per l'esercizio 2025, Standard BioTools prevede ricavi complessivi tra $165-175 million, con ricavi dalle attività continuative tra $78-83 million.
Standard BioTools (NASDAQ:LAB) presentó los resultados financieros del segundo trimestre de 2025, destacando una transformación estratégica con la venta de SomaLogic a Illumina por hasta $425 million en efectivo más regalías futuras. Los ingresos del Q2 procedentes de operaciones continuas fueron de $21.8 million, un descenso del 3% interanual. La compañía informa de $240 million en efectivo y espera contar con al menos $550 million una vez cerrada la transacción con Illumina.
Entre las cifras clave, los ingresos por consumibles fueron de $10.5 million (subieron 18% interanual), por instrumentos $5.2 million (bajaron 26% interanual) y por servicios $6.1 million (bajaron 8% interanual). La pérdida neta mejoró a $17.7 million frente a $25.4 million en el Q2 de 2024. Para el ejercicio 2025, Standard BioTools espera ingresos combinados de $165-175 million, con ingresos de operaciones continuas de $78-83 million.
Standard BioTools (NASDAQ:LAB)는 2025년 2분기 실적을 발표하며 SomaLogic을 Illumina에 최대 $425 million의 현금과 향후 로열티를 조건으로 매각하는 전략적 전환을 강조했습니다. 계속 영업 중인 사업에서의 2분기 매출은 $21.8 million으로 전년 동기 대비 3% 감소했습니다. 회사는 $240 million의 현금을 보유하고 있으며 Illumina 거래 종결 후 최소 $550 million을 확보할 것으로 예상합니다.
주요 지표는 소모품 매출 $10.5 million(전년 대비 18% 증가), 기기 매출 $5.2 million(전년 대비 26% 감소), 서비스 매출 $6.1 million(전년 대비 8% 감소)입니다. 순손실은 2024년 2분기의 $25.4 million에서 개선되어 $17.7 million을 기록했습니다. 2025 회계연도에 Standard BioTools는 총매출을 $165-175 million, 계속 영업 매출을 $78-83 million으로 전망합니다.
Standard BioTools (NASDAQ:LAB) a publié ses résultats du deuxième trimestre 2025, soulignant une transformation stratégique avec la cession de SomaLogic à Illumina pour jusqu'à $425 million en numéraire plus des redevances futures. Le chiffre d'affaires du T2 issu des activités poursuivies s'est élevé à $21.8 million, en baisse de 3% sur un an. La société dispose de $240 million de trésorerie et prévoit au moins $550 million après la clôture de la transaction avec Illumina.
Parmi les indicateurs clés, les revenus liés aux consommables se sont élevés à $10.5 million (en hausse de 18% sur un an), les revenus instruments à $5.2 million (en baisse de 26% sur un an) et les revenus services à $6.1 million (en baisse de 8% sur un an). La perte nette s'est réduite à $17.7 million contre $25.4 million au T2 2024. Pour l'exercice 2025, Standard BioTools anticipe un chiffre d'affaires combiné de $165-175 million, dont $78-83 million provenant des activités poursuivies.
Standard BioTools (NASDAQ:LAB) gab die Finanzergebnisse für das zweite Quartal 2025 bekannt und hebt eine strategische Neuausrichtung durch den Verkauf von SomaLogic an Illumina für bis zu $425 million in bar zuzüglich künftiger Lizenzzahlungen hervor. Die Umsätze aus fortgeführten Geschäftsbereichen im Q2 beliefen sich auf $21.8 million, ein Rückgang von 3% gegenüber dem Vorjahr. Das Unternehmen hält $240 million in bar und rechnet nach Abschluss der Illumina-Transaktion mit mindestens $550 million.
Zu den wichtigen Kennzahlen zählen Erlöse aus Verbrauchsmaterialien von $10.5 million (plus 18% ggü. Vorjahr), Geräteerlöse von $5.2 million (minus 26% ggü. Vorjahr) und Serviceerlöse von $6.1 million (minus 8% ggü. Vorjahr). Der Nettoverlust verbesserte sich auf $17.7 million gegenüber $25.4 million im Q2 2024. Für das Geschäftsjahr 2025 erwartet Standard BioTools einen Gesamtumsatz von $165–175 million und Umsätze aus fortgeführten Geschäftsbereichen von $78–83 million.
- Strategic sale of SomaLogic to Illumina for up to $425 million plus royalties
- Strong cash position of $240 million, expected to reach $550 million post-transaction
- Consumables revenue grew 18% year-over-year to $10.5 million in Q2
- Net loss improved by 31% to $17.7 million compared to Q2 2024
- Gross margins improved to 48.8% from 46.1% year-over-year
- Operating expenses decreased by 11% to $36.3 million year-over-year
- Total revenue declined 3% year-over-year to $21.8 million
- Instruments revenue dropped 26% to $5.2 million
- Services revenue decreased 8% to $6.1 million
- Continued pressure on U.S. Academic spending affecting revenue
- Adjusted EBITDA remains negative at -$16.1 million
- Expects high single-digit millions decline in Americas academic revenue
Insights
Standard BioTools reported mixed Q2 results while announcing a strategic SomaLogic sale to Illumina that substantially strengthens their balance sheet.
Standard BioTools' Q2 2025 results reveal a company in transition, with revenue from continuing operations at
Looking at segment performance, consumables revenue showed strength at
The company's margin profile is improving despite revenue challenges. Non-GAAP gross margins increased to
The net loss narrowed significantly to
For fiscal year 2025, management projects combined revenue of
The SomaLogic divestiture transforms Standard BioTools into a leaner operation with substantial capital for strategic acquisitions. Management explicitly states they plan to deploy this capital toward "high-quality, underappreciated assets" to drive scale and growth, signaling an aggressive inorganic growth strategy ahead.
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the second quarter ended June 30, 2025. Standard BioTools will no longer host its second quarter 2025 earnings call, previously scheduled for Monday, August 11 at 4:30 p.m. ET.
Recent Highlights:
- Second quarter 2025 total combined company revenue of
$42.0 million ; Revenue from continuing operations of$21.8 million - Announced strategic sale of SomaLogic to Illumina for up to
$425 million in total cash consideration plus future royalties, expected to close in the first half of 2026 $240 million in cash & cash equivalents as of June 30, 2025; At least$550 million in cash & cash equivalents expected at close of transaction with Illumina to fuel inorganic growth strategy- Targeting adjusted EBITDA break-even in 2026
“The second quarter was a clear demonstration of our strategy in action. Our team delivered another solid quarter of performance, even as U.S. Academic spend remained under pressure, while taking meaningful steps to transform the business,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “The announced sale of SomaLogic to Illumina marks a pivotal milestone in that evolution – unlocking up to
Egholm continued, “With at least
Financial Results Table: Continuing Operations
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| (Unaudited, in millions, except percentages) | 2025 | 2024 | 2025 | 2024 | |||||||||||
| Revenue | $ | 21.8 | $ | 22.5 | $ | 42.0 | $ | 44.1 | |||||||
| Gross margin | 48.8 | % | 46.1 | % | 51.6 | % | 48.5 | % | |||||||
| Non-GAAP gross margin | 54.1 | % | 48.6 | % | 55.6 | % | 54.1 | % | |||||||
| Operating expenses | $ | 36.3 | $ | 40.6 | $ | 74.3 | $ | 96.1 | |||||||
| Non-GAAP operating expenses | $ | 27.9 | $ | 28.3 | $ | 53.5 | $ | 58.2 | |||||||
| Operating loss | $ | (25.7 | ) | $ | (30.3 | ) | $ | (52.7 | ) | $ | (74.7 | ) | |||
| Net loss from continuing operations | $ | (17.7 | ) | $ | (25.4 | ) | $ | (41.0 | ) | $ | (41.8 | ) | |||
| Adjusted EBITDA | $ | (16.1 | ) | $ | (17.4 | ) | $ | (30.2 | ) | $ | (34.3 | ) | |||
| Cash, cash equivalents, restricted cash, and short-term investments | $ | 239.7 | $ | 397.2 | $ | 239.7 | $ | 397.2 | |||||||
Second Quarter 2025 Financial Results: Continuing Operations
Following the announced sale of SomaLogic in June 2025, all financial results in this section reflect continuing operations only.
- Revenue was
$21.8 million in the second quarter of 2025, down3% year-over-year, and$42 million for the first half of 2025, down5% year-over-year:- Consumables revenue was
$10.5 million in the second quarter of 2025, up18% year-over-year, and$18.6 million for the first half of 2025, down3% year-over-year. Consumables revenue in the quarter increased across imaging, flow and microfluidics product lines. - Instruments revenue was
$5.2 million in the second quarter of 2025, down26% year-over-year, and$11.9 million for the first half of 2025, down1% year-over-year. Instrument revenue in the quarter was impacted by capital constrained end-markets globally. - Services revenue, which is predominantly Field Services, was
$6.1 million in the second quarter of 2025, down8% year-over-year, and$11.5 million for the first half of 2025, down11% year-over-year. Field Services revenue decreased due to fewer active service contracts and lower on-demand revenue driven by improved instrument quality and uptime.
- Consumables revenue was
- Gross margins in the second quarter of 2025 were approximately
48.8% , versus46.1% in the second quarter of 2024; and non-GAAP gross margins in the second quarter of 2025 were approximately54.1% , versus48.6% in the second quarter of 2024. Gross margins in the first half of the year were51.6% in 2025 and48.5% in 2024; and non-GAAP gross margins were approximately55.6% in the first half of 2025 and54.1% for the same period in 2024. Gross margins and non-GAAP gross margins were driven by product mix and incremental improvements from Standard BioTools Business System (SBS). - Operating expenses in the second quarter of 2025 were
$36.3 million , a decrease of$4.3 million , or down11% , compared to the second quarter of 2024; and non-GAAP operating expenses, which exclude transaction costs, stock-based compensation, and restructuring charges, were$27.9 million in the second quarter of 2025, a decrease of$0.4 million , or down1% , compared to the second quarter of 2024. For the first half of 2025, operating expenses decreased by$21.8 million , or23% , compared to the first half of 2024, to$74.3 million , while non-GAAP operating expenses decreased by$4.7 million , or8% , compared to the same period in 2024, to$53.5 million . The decrease in operating expenses is a result of the realization of merger cost synergies and continued productivity gains from SBS. - Net loss for the second quarter of 2025 was
$17.7 million , compared to a net loss of$25.4 million in the second quarter of 2024, representing a decrease of$7.7 million or31% , while adjusted EBITDA for the second quarter of 2025 was a loss of$16.1 million , versus an adjusted EBITDA loss of$17.4 million in the second quarter of 2024, an improvement of$1.2 million , or7% . Net loss for the first half improved by$0.8 million at$41.0 million while adjusted EBITDA increased by$4.1 million , or12% , compared to the first half of 2024, to a loss of$30.2 million .
Full Year 2025 Revenue Outlook
For fiscal year 2025, the Company expects combined revenue in the range of
This combined outlook continues to assume a high single-digit millions decline in our Americas academic revenue due to anticipated NIH funding pressures, with a more pronounced impact on our continuing operations. It also assumes no expected effect from U.S. export controls and limited impact from tariffs.
Conference Call Information
Standard BioTools will no longer host its second quarter 2025 earnings call, previously scheduled for Monday, August 11 at 4:30 p.m. ET. In connection with the pending sale of SomaLogic and operational focus, the Company is temporarily pausing earnings conference calls until further notice.
All financial results and related disclosures are available in this press release and will be available in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”), including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.
Use of Non-GAAP Financial Information
Standard BioTools has presented certain financial information in accordance with U.S. GAAP and on a non-GAAP basis. The non-GAAP financial measures included in this press release are non-GAAP gross margin, non-GAAP gross profit, non-GAAP operating expenses, and adjusted EBITDA. Management uses these non-GAAP financial measures, in addition to GAAP financial measures, as a measure of operating performance because the non-GAAP financial measures do not include the impact of items that management does not consider indicative of the Company’s core operating performance. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the Company’s core operating results. Management uses non-GAAP measures to compare the Company’s performance relative to forecasts and strategic plans and to benchmark the Company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the Company’s operating results as reported under U.S. GAAP. Standard BioTools encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding future financial and business performance, including with respect to future revenue and expected cash at the closing of the transaction with Illumina; operational and strategic plans; deployment of capital; market and growth opportunity and potential; and the potential to realize the expected benefits and synergies of prior and potential future acquisitions, including the potential for such transactions to drive long-term profitable growth. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, risks that the anticipated benefits and synergies of announced divestures and prior and potential future acquisitions and the integration of any such businesses, including the potential for such transactions to drive long-term profitable growth, may not be fully realized or may take longer to realize than expected; risks that the Company may not realize expected cost savings from such transactions; possible integration, restructuring and transition-related disruption resulting from such transactions, including through the loss of customers, suppliers, and employees and adverse impacts on the Company’s development activities and results of operation; the timing of the closing of the transaction with Illumina and the operating expenses over the intervening period; integration and restructuring activities, including customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause the Company to use cash more quickly than it expects or change or curtail some of the Company’s plans, or both; risks that the Company’s expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in the Company’s business or external market conditions; anticipated NIH funding pressures; the expected effect from U.S. export controls and the expected impact from tariffs; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, the Company’s products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary, or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to the Company’s research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. For information regarding other related risks, see the “Risk Factors” section of the Company’s annual report on Form 10-K filed with the SEC on March 11, 2025, the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2025 to be filed with the SEC, and in the Company’s other filings with the SEC. These forward-looking statements speak only as of the date hereof. The Company disclaims any obligation to update these forward-looking statements except as may be required by law.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2025 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
Investor Contact:
ir@standardbio.com
| STANDARD BIOTOOLS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Continuing Operations (In thousands, except per share amounts) (Unaudited) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue: | ||||||||||||||||
| Product revenue | $ | 15,673 | $ | 15,894 | $ | 30,454 | $ | 31,208 | ||||||||
| Services and other revenue | 6,089 | 6,598 | 11,530 | 12,937 | ||||||||||||
| Total revenue | 21,762 | 22,492 | 41,984 | 44,145 | ||||||||||||
| Cost of revenue: | ||||||||||||||||
| Cost of product revenue | 7,608 | 7,771 | 14,039 | 15,617 | ||||||||||||
| Cost of services and other revenue | 3,526 | 4,347 | 6,268 | 7,129 | ||||||||||||
| Total cost of revenue | 11,134 | 12,118 | 20,307 | 22,746 | ||||||||||||
| Gross profit | 10,628 | 10,374 | 21,677 | 21,399 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 6,222 | 7,244 | 11,662 | 14,852 | ||||||||||||
| Selling, general and administrative | 28,105 | 24,860 | 57,929 | 51,274 | ||||||||||||
| Restructuring and related charges | 1,727 | 5,749 | 3,279 | 10,033 | ||||||||||||
| Transaction and integration expenses | 271 | 2,782 | 1,474 | 19,945 | ||||||||||||
| Total operating expenses | 36,325 | 40,635 | 74,344 | 96,104 | ||||||||||||
| Loss from continuing operations | (25,697 | ) | (30,261 | ) | (52,667 | ) | (74,705 | ) | ||||||||
| Bargain purchase gain | — | — | — | 25,213 | ||||||||||||
| Interest income | 2,461 | 5,302 | 5,377 | 11,509 | ||||||||||||
| Interest expense | (9 | ) | (858 | ) | (11 | ) | (1,891 | ) | ||||||||
| Other income (expense), net | 4,963 | 412 | 5,530 | (1,822 | ) | |||||||||||
| Loss from continuing operations before income taxes | (18,282 | ) | (25,405 | ) | (41,771 | ) | (41,696 | ) | ||||||||
| Income tax benefit (expense) | 609 | (39 | ) | 728 | (152 | ) | ||||||||||
| Net loss from continuing operations | (17,673 | ) | (25,444 | ) | (41,043 | ) | (41,848 | ) | ||||||||
| Discontinued operations: | ||||||||||||||||
| Loss from discontinued operations, net of tax | (15,786 | ) | (20,274 | ) | (18,449 | ) | (36,027 | ) | ||||||||
| Net loss | (33,459 | ) | (45,718 | ) | (59,492 | ) | (77,875 | ) | ||||||||
| Induced conversion of redeemable preferred stock | — | — | — | (46,014 | ) | |||||||||||
| Net loss attributable to common stockholders | $ | (33,459 | ) | $ | (45,718 | ) | $ | (59,492 | ) | $ | (123,889 | ) | ||||
| Net loss per share from continuing operations, basic and diluted | $ | (0.05 | ) | $ | (0.07 | ) | $ | (0.11 | ) | $ | (0.26 | ) | ||||
| Net loss per share from discontinued operations, basic and diluted | $ | (0.04 | ) | $ | (0.05 | ) | $ | (0.05 | ) | $ | (0.11 | ) | ||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.09 | ) | $ | (0.12 | ) | $ | (0.16 | ) | $ | (0.37 | ) | ||||
| Shares used in computing net loss per share attributable to common stockholders, basic and diluted | 380,498 | 372,331 | 379,369 | 333,228 | ||||||||||||
| STANDARD BIOTOOLS INC. CONDENSED CONSOLIDATED BALANCE SHEETS Continuing Operations (In thousands) (Unaudited) | ||||||||
| June 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 158,617 | $ | 166,728 | ||||
| Short-term investments | 78,468 | 126,146 | ||||||
| Accounts receivable, net | 14,612 | 14,741 | ||||||
| Inventory | 24,170 | 20,744 | ||||||
| Prepaid expenses and other current assets | 7,081 | 4,561 | ||||||
| Current assets held for sale | 223,089 | 42,963 | ||||||
| Total current assets | 506,037 | 375,883 | ||||||
| Property and equipment, net | 22,678 | 22,775 | ||||||
| Operating lease right-of-use asset, net | 24,568 | 26,567 | ||||||
| Other non-current assets | 3,682 | 3,688 | ||||||
| Non-current assets held for sale | — | 183,432 | ||||||
| Total assets | $ | 556,965 | $ | 612,345 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 7,329 | $ | 5,049 | ||||
| Accrued liabilities | 24,207 | 21,435 | ||||||
| Operating lease liabilities, current | 5,094 | 4,806 | ||||||
| Deferred revenue, current | 40,167 | 10,274 | ||||||
| Deferred grant income, current | 3,243 | 3,527 | ||||||
| Current liabilities held for sale | 17,984 | 20,804 | ||||||
| Total current liabilities | 98,024 | 65,895 | ||||||
| Convertible notes, non-current | 299 | 299 | ||||||
| Deferred tax liability | 1,081 | 1,081 | ||||||
| Operating lease liabilities, non-current | 23,223 | 25,590 | ||||||
| Deferred revenue, non-current | 2,786 | 32,674 | ||||||
| Deferred grant income, non-current | 5,767 | 7,243 | ||||||
| Other non-current liabilities | 1,250 | 1,062 | ||||||
| Non-current liabilities held for sale | — | 6,779 | ||||||
| Total liabilities | 132,430 | 140,623 | ||||||
| Total stockholders’ equity | 424,535 | 471,722 | ||||||
| Total liabilities and stockholders’ equity | $ | 556,965 | $ | 612,345 | ||||
| STANDARD BIOTOOLS INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) | ||||||||
| Six Months Ended June 30, | ||||||||
| 2025 | 2024 | |||||||
| Operating activities | ||||||||
| Net loss | $ | (59,492 | ) | $ | (77,875 | ) | ||
| Bargain purchase gain | — | (25,213 | ) | |||||
| Stock-based compensation expense | 15,396 | 18,341 | ||||||
| Amortization of acquired intangible assets | 1,715 | 2,822 | ||||||
| Depreciation and amortization | 6,450 | 6,228 | ||||||
| Accretion of discount on short-term investments, net | (1,571 | ) | (4,544 | ) | ||||
| Non-cash lease expense | 2,865 | 2,949 | ||||||
| Provision for excess and obsolete inventory | 1,360 | 1,874 | ||||||
| Change in fair value of warrants | (232 | ) | (453 | ) | ||||
| Change in fair value of contingent consideration | (3,400 | ) | — | |||||
| Other non-cash items | 477 | 868 | ||||||
| Changes in assets and liabilities, net | (14,519 | ) | (26,523 | ) | ||||
| Net cash used in operating activities | (50,951 | ) | (101,526 | ) | ||||
| Investing activities | ||||||||
| Cash and restricted cash acquired in merger | — | 280,033 | ||||||
| Purchases of short-term investments | (50,929 | ) | (147,984 | ) | ||||
| Proceeds from sales and maturities of investments | 100,000 | 239,000 | ||||||
| Purchases of property and equipment | (6,941 | ) | (2,718 | ) | ||||
| Net cash provided by investing activities | 42,130 | 368,331 | ||||||
| Financing activities | ||||||||
| Repayment of term loan and convertible notes | — | (8,192 | ) | |||||
| Payment of term loan fee | — | (545 | ) | |||||
| Repurchase of common stock | — | (40,490 | ) | |||||
| Proceeds from ESPP stock issuance | 308 | 425 | ||||||
| Payments for taxes related to net share settlement of equity awards and other | (246 | ) | (344 | ) | ||||
| Proceeds from exercise of stock options | — | 1,052 | ||||||
| Net cash provided by (used in) financing activities | 62 | (48,094 | ) | |||||
| Effect of foreign exchange rate fluctuations on cash and cash equivalents | 1,145 | (110 | ) | |||||
| Net (decrease) increase in cash, cash equivalents and restricted cash | (7,614 | ) | 218,601 | |||||
| Cash, cash equivalents and restricted cash at beginning of period | 168,818 | 52,499 | ||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 161,204 | $ | 271,100 | ||||
| Cash, cash equivalents, and restricted cash consists of: | ||||||||
| Cash and cash equivalents | $ | 158,617 | $ | 269,811 | ||||
| Restricted cash | 2,587 | 1,289 | ||||||
| Total cash, cash equivalents and restricted cash | $ | 161,204 | $ | 271,100 | ||||
| STANDARD BIOTOOLS INC. REVENUE Continuing Operations (In thousands) (Unaudited) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Product revenue: | ||||||||||||||||
| Instruments | $ | 5,215 | $ | 7,047 | $ | 11,861 | $ | 11,950 | ||||||||
| Consumables | 10,458 | 8,847 | 18,593 | 19,258 | ||||||||||||
| Total product revenue | 15,673 | 15,894 | 30,454 | 31,208 | ||||||||||||
| Services and other revenue | 6,089 | 6,598 | 11,530 | 12,937 | ||||||||||||
| Total revenue | $ | 21,762 | $ | 22,492 | $ | 41,984 | $ | 44,145 | ||||||||
| STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION Continuing Operations (In thousands) (Unaudited) ITEMIZED RECONCILIATION OF GROSS PROFIT TO NON-GAAP GROSS PROFIT AND MARGIN PERCENTAGE | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Gross profit | $ | 10,628 | $ | 10,374 | $ | 21,677 | $ | 21,399 | ||||||||
| Amortization of acquired intangible assets | — | 3 | — | 1,407 | ||||||||||||
| Depreciation and amortization | 554 | 332 | 817 | 699 | ||||||||||||
| Stock-based compensation expense | 402 | 221 | 644 | 383 | ||||||||||||
| Loss on disposal of property and equipment | 187 | — | 187 | — | ||||||||||||
| Cost of sales adjustment | — | — | — | — | ||||||||||||
| Non-GAAP gross profit | $ | 11,771 | $ | 10,930 | $ | 23,325 | $ | 23,888 | ||||||||
| Gross margin percentage | 48.8 | % | 46.1 | % | 51.6 | % | 48.5 | % | ||||||||
| Amortization of acquired intangible assets | — | — | — | 3.1 | % | |||||||||||
| Depreciation and amortization | 2.6 | % | 1.5 | % | 2.0 | % | 1.6 | % | ||||||||
| Stock-based compensation expense | 1.8 | % | 1.0 | % | 1.6 | % | 0.9 | % | ||||||||
| Loss on disposal of property and equipment | 0.9 | % | — | 0.4 | % | — | ||||||||||
| Cost of sales adjustment | — | — | — | — | ||||||||||||
| Non-GAAP gross margin percentage | 54.1 | % | 48.6 | % | 55.6 | % | 54.1 | % | ||||||||
| STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION Continuing Operations (In thousands) (Unaudited) ITEMIZED RECONCILIATION OF GAAP TO NON-GAAP OPERATING EXPENSES | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Operating expenses | $ | 36,325 | $ | 40,635 | $ | 74,344 | $ | 96,104 | ||||||||
| Restructuring and related charges | (1,727 | ) | (5,749 | ) | (3,279 | ) | (10,033 | ) | ||||||||
| Transaction and integration expenses | (271 | ) | (2,782 | ) | (1,474 | ) | (19,945 | ) | ||||||||
| Stock-based compensation expense | (4,970 | ) | (3,189 | ) | (12,777 | ) | (6,595 | ) | ||||||||
| Amortization of acquired intangible assets | — | 77 | — | — | ||||||||||||
| Depreciation and amortization | (1,451 | ) | (674 | ) | (3,277 | ) | (1,295 | ) | ||||||||
| Loss on disposal of property and equipment | — | (9 | ) | — | (23 | ) | ||||||||||
| Non-GAAP operating expenses | $ | 27,906 | $ | 28,309 | $ | 53,537 | $ | 58,213 | ||||||||
| R&D operating expenses | $ | 6,222 | $ | 7,244 | $ | 11,662 | $ | 14,852 | ||||||||
| Stock-based compensation expense | (481 | ) | (238 | ) | (820 | ) | (644 | ) | ||||||||
| Depreciation and amortization | (630 | ) | (130 | ) | (769 | ) | (289 | ) | ||||||||
| Gain on disposal of property and equipment | 56 | — | 28 | — | ||||||||||||
| Non-GAAP R&D operating expenses | $ | 5,167 | $ | 6,876 | $ | 10,101 | $ | 13,919 | ||||||||
| SG&A operating expenses | $ | 28,105 | $ | 24,860 | $ | 57,929 | $ | 51,274 | ||||||||
| Stock-based compensation expense | (4,489 | ) | (2,951 | ) | (11,957 | ) | (5,951 | ) | ||||||||
| Amortization of acquired intangible assets | — | 77 | — | — | ||||||||||||
| Depreciation and amortization | (821 | ) | (544 | ) | (2,508 | ) | (1,006 | ) | ||||||||
| Loss on disposal of property and equipment | (56 | ) | (9 | ) | (28 | ) | (23 | ) | ||||||||
| Non-GAAP SG&A operating expenses | $ | 22,739 | $ | 21,433 | $ | 43,436 | $ | 44,294 | ||||||||
| STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION Continuing Operations (In thousands) (Unaudited) ITEMIZED RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net loss | $ | (17,673 | ) | $ | (25,444 | ) | $ | (41,043 | ) | $ | (41,848 | ) | ||||
| Income tax (benefit) expense | (609 | ) | 39 | (728 | ) | 152 | ||||||||||
| Interest income | (2,461 | ) | (5,302 | ) | (5,377 | ) | (11,509 | ) | ||||||||
| Interest expense | 9 | 858 | 11 | 1,891 | ||||||||||||
| Amortization of acquired intangible assets | — | (74 | ) | — | 1,407 | |||||||||||
| Depreciation and amortization | 2,005 | 1,006 | 4,094 | 1,994 | ||||||||||||
| Bargain purchase gain | — | — | — | (25,213 | ) | |||||||||||
| Restructuring and related charges | 1,727 | 5,749 | 3,279 | 10,033 | ||||||||||||
| Transaction and integration expenses | 271 | 2,782 | 1,474 | 19,945 | ||||||||||||
| Stock-based compensation expense | 5,372 | 3,410 | 13,421 | 6,978 | ||||||||||||
| Cost of sales adjustment | — | — | — | — | ||||||||||||
| Loss on disposal of property and equipment | 187 | 9 | 187 | 23 | ||||||||||||
| Other non-operating (income) expense | (4,963 | ) | (412 | ) | (5,530 | ) | 1,822 | |||||||||
| Adjusted EBITDA | $ | (16,135 | ) | $ | (17,379 | ) | $ | (30,212 | ) | $ | (34,325 | ) | ||||
| STANDARD BIOTOOLS INC. Condensed Results of Operations Discontinued Operations (In thousands) (Unaudited) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue | $ | 20,200 | $ | 14,713 | $ | 40,773 | $ | 38,600 | ||||||||
| Cost of revenue | 11,552 | 10,176 | 23,432 | 20,904 | ||||||||||||
| Selling, general and administrative expenses | 8,216 | 12,849 | 17,099 | 33,378 | ||||||||||||
| Research and development | 5,850 | 11,977 | 11,738 | 20,350 | ||||||||||||
| Transaction and integration expenses | 10,507 | - | 10,507 | - | ||||||||||||
| Other (income) expense, net | (139 | ) | (15 | ) | (3,554 | ) | (5 | ) | ||||||||
| Total expenses | $ | 35,986 | $ | 34,987 | $ | 59,222 | $ | 74,627 | ||||||||
| Loss from discontinued operations | $ | (15,786 | ) | $ | (20,274 | ) | $ | (18,449 | ) | $ | (36,027 | ) | ||||
| STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION Discontinued Operations (In thousands) (Unaudited) ITEMIZED RECONCILIATION OF GROSS PROFIT TO NON-GAAP GROSS PROFIT AND MARGIN PERCENTAGE | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Gross profit | $ | 8,649 | $ | 4,534 | $ | 17,342 | $ | 17,697 | ||||||||
| Amortization of acquired intangible assets | 653 | 552 | 1,370 | 1,104 | ||||||||||||
| Depreciation and amortization | 879 | 635 | 1,352 | 1,292 | ||||||||||||
| Stock-based compensation expense | 161 | 73 | 414 | 150 | ||||||||||||
| Loss on disposal of property and equipment | 26 | — | 58 | — | ||||||||||||
| Cost of sales adjustment | — | — | — | (1,812 | ) | |||||||||||
| Non-GAAP gross profit | $ | 10,368 | $ | 5,794 | $ | 20,536 | $ | 18,431 | ||||||||
| Gross margin percentage | 42.8 | % | 30.8 | % | 42.5 | % | 45.8 | % | ||||||||
| Amortization of acquired intangible assets | 3.2 | % | 3.8 | % | 3.5 | % | 2.9 | % | ||||||||
| Depreciation and amortization | 4.4 | % | 4.3 | % | 3.3 | % | 3.3 | % | ||||||||
| Stock-based compensation expense | 0.8 | % | 0.5 | % | 1.0 | % | 0.4 | % | ||||||||
| Loss on disposal of property and equipment | 0.1 | % | — | 0.1 | % | — | ||||||||||
| Cost of sales adjustment | — | — | — | (4.7 | )% | |||||||||||
| Non-GAAP gross margin percentage | 51.3 | % | 39.4 | % | 50.4 | % | 47.7 | % | ||||||||
| STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION Discontinued Operations (In thousands) (Unaudited) ITEMIZED RECONCILIATION OF GAAP TO NON-GAAP OPERATING EXPENSES | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Operating expenses | $ | 24,756 | $ | 24,792 | $ | 39,448 | $ | 53,693 | ||||||||
| Restructuring and related charges | (104 | ) | — | (104 | ) | — | ||||||||||
| Transaction and integration expenses | (10,507 | ) | — | (10,507 | ) | — | ||||||||||
| Stock-based compensation expense | (852 | ) | (3,247 | ) | (1,561 | ) | (11,213 | ) | ||||||||
| Amortization of acquired intangible assets | (164 | ) | (238 | ) | (345 | ) | (311 | ) | ||||||||
| Depreciation and amortization | (293 | ) | (1,498 | ) | (1,004 | ) | (2,942 | ) | ||||||||
| Loss on disposal of property and equipment | (36 | ) | (362 | ) | (190 | ) | (362 | ) | ||||||||
| Non-GAAP operating expenses | $ | 12,800 | $ | 19,447 | $ | 25,737 | $ | 38,865 | ||||||||
| R&D operating expenses | $ | 5,850 | $ | 11,978 | $ | 11,738 | $ | 20,350 | ||||||||
| Stock-based compensation expense | (479 | ) | (2,190 | ) | (881 | ) | (3,112 | ) | ||||||||
| Depreciation and amortization | (392 | ) | (658 | ) | (843 | ) | (1,370 | ) | ||||||||
| Loss on disposal of property and equipment | (26 | ) | — | (166 | ) | — | ||||||||||
| Non-GAAP R&D operating expenses | $ | 4,953 | $ | 9,130 | $ | 9,848 | $ | 15,868 | ||||||||
| SG&A operating expenses | $ | 8,295 | $ | 12,814 | $ | 17,099 | $ | 33,343 | ||||||||
| Stock-based compensation expense | (373 | ) | (1,057 | ) | (680 | ) | (8,101 | ) | ||||||||
| Amortization of acquired intangible assets | (164 | ) | (238 | ) | (345 | ) | (311 | ) | ||||||||
| Depreciation and amortization | 99 | (840 | ) | (161 | ) | (1,572 | ) | |||||||||
| Loss on disposal of property and equipment | (10 | ) | (362 | ) | (24 | ) | (362 | ) | ||||||||
| Non-GAAP SG&A operating expenses | $ | 7,847 | $ | 10,317 | $ | 15,889 | $ | 22,997 | ||||||||
| STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION Discontinued Operations (In thousands) (Unaudited) ITEMIZED RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net loss | $ | (15,786 | ) | $ | (20,274 | ) | $ | (18,449 | ) | $ | (36,027 | ) | ||||
| Income tax (benefit) expense | (125 | ) | 16 | (157 | ) | 31 | ||||||||||
| Interest income | — | — | — | — | ||||||||||||
| Interest expense | — | — | — | — | ||||||||||||
| Amortization of acquired intangible assets | 817 | 790 | 1,715 | 1,415 | ||||||||||||
| Depreciation and amortization | 1,172 | 2,133 | 2,356 | 4,234 | ||||||||||||
| Bargain purchase gain | — | — | — | — | ||||||||||||
| Restructuring and related charges | 104 | — | 104 | — | ||||||||||||
| Transaction and integration expenses | 10,507 | — | 10,507 | — | ||||||||||||
| Stock-based compensation expense | 1,013 | 3,320 | 1,975 | 11,363 | ||||||||||||
| Cost of sales adjustment | — | — | — | (1,812 | ) | |||||||||||
| Loss on disposal of property and equipment | 62 | 362 | 248 | 362 | ||||||||||||
| Other non-operating (income) expense | (196 | ) | — | (3,500 | ) | — | ||||||||||
| Adjusted EBITDA | $ | (2,432 | ) | $ | (13,653 | ) | $ | (5,201 | ) | $ | (20,434 | ) | ||||
| STANDARD BIOTOOLS INC. Condensed Combined Results of Operations Continuing Operations and Discontinued Operations (In thousands) (Unaudited) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue | $ | 41,962 | $ | 37,205 | $ | 82,757 | $ | 82,745 | ||||||||
| Cost of revenue | 22,686 | 22,294 | 43,739 | 43,650 | ||||||||||||
| Selling, general and administrative expenses | 36,321 | 37,709 | 75,028 | 84,652 | ||||||||||||
| Research and development | 12,072 | 19,221 | 23,400 | 35,202 | ||||||||||||
| Transaction and integration expenses | 10,778 | 2,782 | 11,981 | 19,945 | ||||||||||||
| Restructuring | 1,727 | 5,749 | 3,279 | 10,033 | ||||||||||||
| Other (income) expense, net | (8,163 | ) | (4,832 | ) | (15,178 | ) | (32,862 | ) | ||||||||
| Total expenses | $ | 75,421 | $ | 82,923 | $ | 142,249 | $ | 160,620 | ||||||||
| Net loss | $ | (33,459 | ) | $ | (45,718 | ) | $ | (59,492 | ) | $ | (77,875 | ) | ||||
| STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION Continuing Operations and Discontinued Operations (In thousands) (Unaudited) ITEMIZED RECONCILIATION OF GROSS PROFIT TO NON-GAAP GROSS PROFIT AND MARGIN PERCENTAGE | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Gross profit | $ | 19,277 | $ | 14,908 | $ | 39,019 | $ | 39,096 | ||||||||
| Amortization of acquired intangible assets | 653 | 555 | 1,370 | 2,511 | ||||||||||||
| Depreciation and amortization | 1,433 | 967 | 2,169 | 1,991 | ||||||||||||
| Stock-based compensation expense | 563 | 294 | 1,058 | 533 | ||||||||||||
| Loss on disposal of property and equipment | 213 | — | 245 | — | ||||||||||||
| Cost of sales adjustment | — | — | — | (1,812 | ) | |||||||||||
| Non-GAAP gross profit | $ | 22,139 | $ | 16,724 | $ | 43,861 | $ | 42,319 | ||||||||
| Gross margin percentage | 45.9 | % | 40.1 | % | 47.1 | % | 47.2 | % | ||||||||
| Amortization of acquired intangible assets | 1.6 | % | 1.5 | % | 1.7 | % | 3.0 | % | ||||||||
| Depreciation and amortization | 3.5 | % | 2.6 | % | 2.6 | % | 2.4 | % | ||||||||
| Stock-based compensation expense | 1.3 | % | 0.8 | % | 1.3 | % | 0.6 | % | ||||||||
| Loss on disposal of property and equipment | 0.5 | % | — | 0.3 | % | — | ||||||||||
| Cost of sales adjustment | — | — | — | (2.1 | )% | |||||||||||
| Non-GAAP gross margin percentage | 52.8 | % | 45.0 | % | 53.0 | % | 51.1 | % | ||||||||
| STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION Continuing Operations and Discontinued Operations (In thousands) (Unaudited) ITEMIZED RECONCILIATION OF GAAP TO NON-GAAP OPERATING EXPENSES | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Operating expenses | $ | 61,081 | $ | 65,427 | $ | 113,792 | $ | 149,797 | ||||||||
| Restructuring and related charges | (1,831 | ) | (5,749 | ) | (3,383 | ) | (10,033 | ) | ||||||||
| Transaction and integration expenses | (10,778 | ) | (2,782 | ) | (11,981 | ) | (19,945 | ) | ||||||||
| Stock-based compensation expense | (5,822 | ) | (6,436 | ) | (14,338 | ) | (17,808 | ) | ||||||||
| Amortization of acquired intangible assets | (164 | ) | (161 | ) | (345 | ) | (311 | ) | ||||||||
| Depreciation and amortization | (1,744 | ) | (2,172 | ) | (4,281 | ) | (4,237 | ) | ||||||||
| Loss on disposal of property and equipment | (36 | ) | (371 | ) | (190 | ) | (385 | ) | ||||||||
| Non-GAAP operating expenses | $ | 40,706 | $ | 47,756 | $ | 79,274 | $ | 97,078 | ||||||||
| R&D operating expenses | $ | 12,072 | $ | 19,222 | $ | 23,400 | $ | 35,202 | ||||||||
| Stock-based compensation expense | (960 | ) | (2,428 | ) | (1,701 | ) | (3,756 | ) | ||||||||
| Depreciation and amortization | (1,022 | ) | (788 | ) | (1,612 | ) | (1,659 | ) | ||||||||
| Loss on disposal of property and equipment | 30 | — | (138 | ) | — | |||||||||||
| Non-GAAP R&D operating expenses | $ | 10,120 | $ | 16,006 | $ | 19,949 | $ | 29,787 | ||||||||
| SG&A operating expenses | $ | 36,400 | $ | 37,674 | $ | 75,028 | $ | 84,617 | ||||||||
| Stock-based compensation expense | (4,862 | ) | (4,008 | ) | (12,637 | ) | (14,052 | ) | ||||||||
| Amortization of acquired intangible assets | (164 | ) | (161 | ) | (345 | ) | (311 | ) | ||||||||
| Depreciation and amortization | (722 | ) | (1,384 | ) | (2,669 | ) | (2,578 | ) | ||||||||
| Loss on disposal of property and equipment | (66 | ) | (371 | ) | (52 | ) | (385 | ) | ||||||||
| Non-GAAP SG&A operating expenses | $ | 30,586 | $ | 31,750 | $ | 59,325 | $ | 67,291 | ||||||||
| STANDARD BIOTOOLS INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION Continuing Operations and Discontinued Operations (In thousands) (Unaudited) ITEMIZED RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net loss | $ | (33,459 | ) | $ | (45,718 | ) | $ | (59,492 | ) | $ | (77,875 | ) | ||||
| Income tax (benefit) expense | (734 | ) | 55 | (885 | ) | 183 | ||||||||||
| Interest income | (2,461 | ) | (5,302 | ) | (5,377 | ) | (11,509 | ) | ||||||||
| Interest expense | 9 | 858 | 11 | 1,891 | ||||||||||||
| Amortization of acquired intangible assets | 817 | 716 | 1,715 | 2,822 | ||||||||||||
| Depreciation and amortization | 3,177 | 3,139 | 6,450 | 6,228 | ||||||||||||
| Bargain purchase gain | — | — | — | (25,213 | ) | |||||||||||
| Restructuring and related charges | 1,831 | 5,749 | 3,383 | 10,033 | ||||||||||||
| Transaction and integration expenses | 10,778 | 2,782 | 11,981 | 19,945 | ||||||||||||
| Stock-based compensation expense | 6,385 | 6,730 | 15,396 | 18,341 | ||||||||||||
| Cost of sales adjustment | — | — | — | (1,812 | ) | |||||||||||
| Loss on disposal of property and equipment | 249 | 371 | 435 | 385 | ||||||||||||
| Other non-operating (income) expense | (5,159 | ) | (412 | ) | (9,030 | ) | 1,822 | |||||||||
| Adjusted EBITDA | $ | (18,567 | ) | $ | (31,032 | ) | $ | (35,413 | ) | $ | (54,759 | ) | ||||
FAQ
What are Standard BioTools (LAB) Q2 2025 earnings results?
How much is Illumina paying for Standard BioTools' SomaLogic unit?
What is Standard BioTools' revenue guidance for 2025?
How did Standard BioTools' different revenue segments perform in Q2 2025?
When will Standard BioTools achieve profitability?
